Development Pipeline

In vitro screening	In vivo / animal studies	Clinical trials		
Discovery Efficacy / tox	Toxicology Efficacy	Phase-I	Phase-II	 Phase-III
NI01: MRSA decolonisation		 		
NIO1: Impetigo, acnes				
NI02: Dermatitis				
NI03: A. baumannii		 		'
AI01: C. difficile		 		
20+ Al-generated lead compounds	Potential markets >	\$10B		

